Federal agencies have released the Affordable Care Act (ACA) and IRS indexed limits applicable to plan years beginning on or after January 1, 2027. Given the significant increase in the ACA Maximum Out-of-Pocket (MOOP) limits for 2027…
Generic tofacitinib (Xeljanz®) has officially entered the market – an important shift in the JAK inhibitor category. With launches across multiple manufacturers…
As biosimilars continue to reshape the market, plan sponsors are looking for real savings – without added complexity. ProAct’s new BioPathways™ Program delivers targeted, clinically-aligned utilization management…
On April 23, 2026, the FDA granted accelerated approval to Otarmeni™ (lunsotogene parvec‑cwha) from Regeneron Pharmaceuticals – the first FDA‑approved gene therapy for patients with…
Gene therapy is an emerging class of treatment that targets disease at its source by repairing or replacing a faulty gene. Unlike traditional drugs that require ongoing use, many gene therapies…
